Tags : Quarterly

Teva’s AJOVY Receives FDA Approval for the Treatment of Migraine

Shots: AJOVY (remanezumab-vfrm) is evaluated in two P-III trial enrolling patients with disabling migraine, administering AJOVY alone and in combination with oral preventive treatments, showing reduction in monthly migraine days in 12 wks. duration having injection site reactions as adverse effects The US Wholesale Acquisition Cost (WAC) of AJOVY for monthly and the quarterly dose […]Read More